138 related articles for article (PubMed ID: 26607327)
1. The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
Aloia A; Petrova E; Tomiuk S; Bissels U; Déas O; Saini M; Zickgraf FM; Wagner S; Spaich S; Sütterlin M; Schneeweiss A; Reitberger M; Rüberg S; Gerstmayer B; Agorku D; Knöbel S; Terranegra A; Falleni M; Soldati L; Sprick MR; Trumpp A; Judde JG; Bosio A; Cairo S; Hardt O
Breast Cancer Res; 2015 Nov; 17(1):146. PubMed ID: 26607327
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.
Wang X; Liu Y; Zhou K; Zhang G; Wang F; Ren J
Int J Clin Exp Pathol; 2015; 8(5):5105-12. PubMed ID: 26191205
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
5. Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft.
Skrbo N; Hjortland GO; Kristian A; Holm R; Nord S; Prasmickaite L; Engebraaten O; Mælandsmo GM; Sørlie T; Andersen K
PLoS One; 2014; 9(11):e113278. PubMed ID: 25419568
[TBL] [Abstract][Full Text] [Related]
6. Platelets surrounding primary tumor cells are related to chemoresistance.
Ishikawa S; Miyashita T; Inokuchi M; Hayashi H; Oyama K; Tajima H; Takamura H; Ninomiya I; Ahmed AK; Harman JW; Fushida S; Ohta T
Oncol Rep; 2016 Aug; 36(2):787-94. PubMed ID: 27349611
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer.
Hara J; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncol Rep; 2014 Feb; 31(2):589-96. PubMed ID: 24297447
[TBL] [Abstract][Full Text] [Related]
8. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific embryonic antigen 4 in Wharton's jelly-derived mesenchymal stem cells is not a marker for proliferation and multipotency.
He H; Nagamura-Inoue T; Tsunoda H; Yuzawa M; Yamamoto Y; Yorozu P; Agata H; Tojo A
Tissue Eng Part A; 2014 Apr; 20(7-8):1314-24. PubMed ID: 24279891
[TBL] [Abstract][Full Text] [Related]
10. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
[TBL] [Abstract][Full Text] [Related]
11. Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.
Ma G; Huang H; Li M; Li L; Kong P; Zhu Y; Xia T; Wang S
Cancer Biomark; 2018; 22(3):405-415. PubMed ID: 29758926
[TBL] [Abstract][Full Text] [Related]
12. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
Bulfoni M; Gerratana L; Del Ben F; Marzinotto S; Sorrentino M; Turetta M; Scoles G; Toffoletto B; Isola M; Beltrami CA; Di Loreto C; Beltrami AP; Puglisi F; Cesselli D
Breast Cancer Res; 2016 Mar; 18(1):30. PubMed ID: 26961140
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
15. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
16. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
18. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
20. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
